Squarepoint Ops LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $13.8 Million - $15.1 Million	354,333 Added 386.47%	446,018 $18.2 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $388,114 - $410,805	9,494 Added 11.55%	91,685 $3.88 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $1.67 Million - $3.49 Million	82,191 New	82,191 $3.48 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $490,721 - $759,521	-21,504 Reduced 39.97%	32,300 $787,000
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $475,059 - $598,930	-18,740 Reduced 25.83%	53,804 $1.7 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.85 Million - $3 Million	72,544 New	72,544 $2.05 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $193,889 - $349,321	-9,403 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $6,204 - $9,340	264 Added 2.89%	9,403 $329,000
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $1.94 Million - $2.96 Million	-66,248 Reduced 87.88%	9,139 $296,000
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $1.6 Million - $2.93 Million	75,387 New	75,387 $2.22 Million

5.04M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.